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The neuro-anatomical substrates of major depressive disorder (MDD) are still not well understood, despite many neuroimaging
studies over the past few decades. Here we present the largest ever worldwide study by the ENIGMA (Enhancing Neuro Imaging
Genetics through Meta-Analysis) Major Depressive Disorder Working Group on cortical structural alterations in MDD. Structural
T1-weighted brain magnetic resonance imaging (MRI) scans from 2148 MDD patients and 7957 healthy controls were analysed with
harmonized protocols at 20 sites around the world. To detect consistent effects of MDD and its modulators on cortical thickness
and surface area estimates derived from MRI, statistical effects from sites were meta-analysed separately for adults and adolescents.
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Adults with MDD had thinner cortical gray matter than controls in the orbitofrontal cortex (OFC), anterior and posterior cingulate,
insula and temporal lobes (Cohen’s d effect sizes: − 0.10 to − 0.14). These effects were most pronounced in ﬁrst episode and adult-
onset patients (421 years). Compared to matched controls, adolescents with MDD had lower total surface area (but no differences
in cortical thickness) and regional reductions in frontal regions (medial OFC and superior frontal gyrus) and primary and higher-
order visual, somatosensory and motor areas (d: − 0.26 to − 0.57). The strongest effects were found in recurrent adolescent patients.
This highly powered global effort to identify consistent brain abnormalities showed widespread cortical alterations in MDD patients
as compared to controls and suggests that MDD may impact brain structure in a highly dynamic way, with different patterns of
alterations at different stages of life.
Molecular Psychiatry advance online publication, 3 May 2016; doi:10.1038/mp.2016.60
INTRODUCTION
Major depressive disorder (MDD) is the single most common
psychiatric disorder, affecting approximately 350 million people
each year.1 Even so, its pathogenesis and proﬁle of effects in the
brain are still not clear. Therefore, in 2013, we initiated the MDD
Working Group within the Enhancing Neuro Imaging Genetics
through Meta-Analysis (ENIGMA) consortium (http://enigma.ini.
usc.edu/) in which researchers around the world collaborate to
boost statistical power to elucidate brain abnormalities in MDD.
Recently, we reported subcortical volume differences between
MDD patients and healthy controls that were related to clinical
characteristics, based on data from 8927 individuals using an
individual participant data-based meta-analysis approach. Sub-
cortical volume differences were the greatest in the hippocampus,
with the strongest effects in recurrent or early-onset patients.2
Here we present results on cortical structural differences in an
even larger sample (N= 10 105).
With regard to cortical structural abnormalities in MDD, prior
magnetic resonance imaging (MRI) studies, summarized in retro-
spective meta-analyses of individually published works, mainly
implicate the (para)limbic circuitry, including dorsomedial pre-
frontal cortex (PFC), orbitofrontal cortex (OFC) and (rostral)
anterior cingulate cortex (ACC), albeit with large variability across
studies.3–7 Findings are inconclusive regarding the temporal and
lateral PFC.4,8 Inconsistencies arise owing to differences in
scanning and analysis methods, the limited power to detect
subtle effects in small samples and clinical variations in medica-
tion status,6 lifetime disease burden,6 age at disease onset9 and
adult vs adolescent study samples.10
Differences in data acquisition protocols and processing and
differences in statistical analyses performed are a key source of
heterogeneity. For example, different techniques for assessing
morphometric deﬁcits in MDD are used. Many studies use
automated MRI analyses such as voxel-based morphometry,11
which avoid labour-intensive manual tracings and improve
reproducibility. Others use surface-based methods that generate
detailed maps of cortical thickness and surface area, which may
differ in their underlying cellular mechanisms and genetic
control.12 In addition, retrospective meta-analyses sometimes only
include focused or hypothesis-driven studies adopting a region of
interest approach (for example, ACC, OFC) with no information on
other regions or studies that use coarse or unspeciﬁc anatomical
regions such as ‘frontal lobe’.3–8 These approaches may not
resolve more subtle or localized patterns of effects.
Here we addressed some of these issues by performing the
largest coordinated worldwide meta-analysis of cortical structural
abnormalities in patients diagnosed with MDD relative to healthy
controls. We extracted cortical thickness and surface area
estimates in 2148 MDD patients and 7957 healthy individuals
using harmonized data analysis strategies across all sites.13
Compared to healthy controls, adult MDD studies generally report
cortical thinning, but adolescent MDD studies have reported both
cortical thinning and thickening14–17 during mid-to-late adoles-
cence. These apparent differences prompted us to analyse
adolescent and adult patients separately, with adults deﬁned here
as individuals aged 421 years. We set the age cut-off for adult
versus adolescent analyses at ⩽ 21 years, based on 1) evidence of
accelerated cortical thinning followed by decelerated thinning in
young adulthood during normal brain development18 and 2) the
presence of a positive correlation between depressive symptoms
and ventromedial PFC in individuals with MDD up to 22 years old.19
Additional stratifying variables were single vs recurrent episodes,
antidepressant medication use, index episode severity and, in the
adult sample, adolescent- vs adult-onset.
MATERIALS AND METHODS
Samples
The ENIGMA MDD Working Group currently includes 20 international
groups with neuroimaging and clinical data from MDD patients and
healthy controls (participating sites are mapped in Supplementary
Figure S1). Overall, we analysed data from 10 105 people, including 2148
MDD patients and 7957 healthy controls. Each sample’s demographics are
detailed in Supplementary Table S1 and clinical characteristics in
Supplementary Table S2. Supplementary Table S3 lists exclusion criteria
for study enrolment. All participating sites obtained approval from local
institutional review boards and ethics committees, and all study
participants provided written informed consent.
Image processing and analysis
Structural T1-weighted MRI brain scans were acquired at each site and
analysed locally using harmonized analysis and quality-control protocols
from the ENIGMA consortium; in this case, all cortical parcellations were
performed with the freely available and validated segmentation software
FreeSurfer (versions 5.1 and 5.3).20 Image acquisition parameters and
software descriptions are given in Supplementary Table S4. Segmentations
of 68 (34 left and 34 right) cortical gray matter regions based on the
Desikan–Killiany atlas21 and two whole-hemisphere measures were visually
inspected and statistically evaluated for outliers following standardized
ENIGMA protocols (http://enigma.ini.usc.edu/protocols/imaging-protocols).
Further details on image exclusion criteria and quality control may be
found in Supplementary Information SI1.
Statistical framework for meta-analysis
We examined group differences in cortical thickness and surface area
between patients and controls within each sample using multiple linear
regression models. In the primary analysis, the outcome measures were
from each of 70 cortical regions of interest (68 regions and two whole-
hemisphere average thickness or total surface area measures). A binary
indicator of diagnosis (0 = controls, 1 = patients) was the predictor of
interest. All models were adjusted for age and sex. Additional covariates
were included whenever necessary to control for scanner differences
within each sample. To ease comparisons with prior work,2,22 effect size
estimates were calculated using Cohen’s d metric computed from the
t-statistic of the diagnosis indicator variable from the regression models.
Similarly, for models testing interactions (that is, sex-by-diagnosis and
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age-by-diagnosis) a multiplicative predictor was the predictor of interest
with the main effect of each predictor included in the model and the effect
size was calculated using the same procedure.
To detect potentially different effects of major depression with age, we
separately analysed adolescent (age ⩽ 21 years) and adult participants
(421 years). Within the adolescent and adult divisions, we tested stratiﬁed
models that split patients based on stage of illness (ﬁrst episode vs
recurrent). Furthermore, we examined associations between symptom
severity at the time of scanning using the 17-item Hamilton Depression
Rating Scale (HDRS-17)23 and the Beck Depression Inventory (BDI-II)24 and
cortical thickness and surface area. Within the adult division, we stratiﬁed
patients based on age at illness onset (adolescent-onset ⩽ 21 years; adult-
onset 421 years25). Results of models that split patients based on
antidepressant use at the time of their scan are reported in Supplementary
Information SI1. Included samples and total sample sizes for each model
are listed in the tables in 'Results' section. Throughout the manuscript, we
report P-values corrected for multiple comparisons using the Benjamini–
Hochberg procedure26 to ensure a false-discovery rate (FDR) limited at 5%
for 70 measures (34 left hemisphere regions, 34 right hemisphere regions
and 2 full-hemisphere measures, for left and right).
All regression models and effects size estimates were computed at each
site separately and a ﬁnal Cohen’s d effect size estimate was obtained
using an inverse variance-weighted random-effect meta-analysis model
in R (metafor package, version 1.9-118). Only for the meta-analyses on
correlation with symptom severity scores and number of episodes in
recurrent patients, predictors were treated as continuous variables, so
effect sizes were expressed as partial-correlation Pearson's r after removing
nuisance variables (age, sex, and scan site). The ﬁnal meta-analysed partial-
correlation r was estimated with the same inverse variance-weighted
random-effect meta-analysis model. See Supplementary Information SI1
for full meta-analysis details.
Moderator analyses with meta-regression
The methods and results of the moderator analyses, using meta-regression
analyses to test whether individual site characteristics explained a
signiﬁcant proportion of the variance in effect sizes across sites in the
meta-analyses, are reported in Supplementary Information SI1.
RESULTS
Adults
Cortical thickness and surface area differences between MDD
patients and controls. We found signiﬁcant and consistent
thinner cortices in the frontal and temporal lobes of adult
depressed patients (N= 1902) compared to controls (N= 7658) in
the bilateral medial OFC, fusiform gyrus, insula, rostral anterior and
posterior cingulate cortex and unilaterally in the left middle
temporal gyrus, right inferior temporal gyrus and right caudal ACC
(see Figure 1 for signiﬁcant regions, Supplementary Figure S11 for
forest plots and Table 1 for full cortical thickness effects). Regions
are listed in all tables in order of effect size, from the strongest to
the weakest effect size. None of the regions analysed showed
signiﬁcant differences in cortical surface area (Supplementary
Table S19) or evidence of sex-by-diagnosis or age-by-diagnosis
interaction effects (Supplementary Tables S5, S6, S20 and S21).
First vs recurrent episode adult MDD. Adult patients with recurrent
depression (N= 1302) compared to controls (N= 7450) revealed
cortical thinning in left medial OFC (Supplementary Figures S2
and S12). First-episode patients (N= 535) compared to controls
(N= 7253) showed more widespread cortical thinning in
bilateral fusiform gyrus, rostral ACC and insula and left medial
orbitofrontal and superior frontal cortex, right caudal anterior
and posterior cingulate cortex and right isthmus cingulate
cortex (Supplementary Figures S3 and S13). No differences
were detected between recurrent and ﬁrst-episode patients
(Supplementary Table S9). Similar to the overall MDD group
analysis, no cortical surface area differences were detected
(Supplementary Tables S22–S24), and we found no signiﬁ-
cant correlations between thickness and surface area and the
number of depressive episodes in recurrent patients (N= 496;
Supplementary Table S10).
Age of onset in adult MDD. Cortical thinning was observed in
patients with an adult age of illness onset (421 years, N= 1214)
compared to controls (N= 3329) in bilateral insula, rostral anterior,
posterior and isthmus cingulate cortex, fusiform gyrus, medial
OFC, right caudal ACC and right inferior temporal gyrus
(Supplementary Figures S4 and S14). We did not detect signiﬁcant
differences in cortical thickness in patients with an adolescent age
of onset (⩽21 years, N= 472), compared to controls (N= 2885),
(Supplementary Table S12) and when comparing adolescent-
onset and adult-onset patients directly (Supplementary Table S13).
Similarly, no surface area differences were detected in these
subgroup analyses (Supplementary Tables S26–S28).
Correlation with symptom severity in adult patients. None of the
cortical thickness measurements were correlated with symptom
severity at study inclusion using the HDRS-17 (N= 776) and BDI-II
(N= 943) questionnaires (Supplementary Tables S17 and S18). For
surface area measurements, no associations were found with the
HDRS-17 (Supplementary Table S32) and weak negative correla-
tions were detected for BDI-II scores and surface area of the
bilateral precuneus, left frontal pole and left postcentral gyrus
(Supplementary Table S33, Supplementary Figures S7 and S17).
Adolescents
Cortical thickness and surface area differences between adolescent
MDD patients and controls. Left and right hemisphere total surface
area was smaller in depressed adolescent patients (N=213)
compared to adolescent controls (N=294). Regionally, surface area
reductions were observed in bilateral lingual gyrus and pericalcar-
ine gyrus, left lateral occipital cortex, left medial OFC, left precentral
gyrus, right inferior parietal cortex, right superior frontal gyrus and
right postcentral gyrus (see Figure 2 and Supplementary Figure S18
and Table 2 for full tabulation of effects). No cortical thickness
differences were detected between adolescent MDD patients and
controls (Supplementary Table S34). Further, no cortical regions
showed age-by-diagnosis or sex-by-diagnosis interaction effects
(Supplementary Tables S35, S36, S45 and S46).
First vs recurrent episode adolescent MDD. Adolescents with
recurrent depression (N= 104) showed reductions in left and right
hemisphere overall surface area compared to controls (N= 142).
Regionally, surface area reductions were observed in bilateral
inferior parietal cortex and caudal middle frontal gyrus and left
fusiform gyrus, left lateral occipital cortex, left precuneus, left
Figure 1. Meta-analysis effect sizes for regions with a signiﬁcant
(PFDRo0.05) cortical thinning in adult major depressive disorder
(MDD) patients compared to healthy controls. Negative effect sizes d
indicate cortical thinning in MDD compared to controls.
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superior parietal cortex, left medial OFC, right banks of the
superior temporal sulcus, right lingual gyrus, right pericalcarine
gyrus and right postcentral gyrus (Supplementary Figures S8 and
S19, Supplementary Table S48). First-episode patients (N= 80)
showed no detectable differences, when compared to controls
(N= 154) or the recurrent adolescent MDD group (Supplementary
Tables S47 and S49). No cortical thickness differences were found
in adolescent MDD for ﬁrst-episode or recurrence subgroups
(Supplementary Tables S37–S39); similarly, no correlations with
the number of episodes were detected for surface area or
thickness in recurrent adolescent MDD patients (Supplementary
Tables S40 and S50).
Correlations with symptom severity in adolescent MDD. We did not
detect signiﬁcant differences in cortical thickness or surface
area when examining the effects of symptom severity at
study inclusion using the HDRS-17 (N= 134) questionnaire
(Supplementary Tables S44 and S54), whereas BDI-II scores were
available only for a small group of adolescent patients (N= 31),
precluding meaningful comparisons.
Moderating effects on cortical thickness and surface area
Results of the moderator analyses can be found in the Supple-
mentary Information.
DISCUSSION
In the largest analysis to date of cortical structural measures, we
applied an individual participant data-based meta-analytic
approach to brain MRI data from 410 000 people, of whom
around one-ﬁfth were affected by MDD. We found signiﬁcant
differences in cortical brain structures in adolescent and adult
MDD and speciﬁc associations with clinical characteristics.
Cortical thickness
Adult MDD patients had cortical thickness deﬁcits in 13 (of 68)
regions examined. Cortical thinning was generally observed
bilaterally, in regions that encompassed the medial PFC, rostral
anterior and posterior cingulate cortex, insula and fusiform gyrus.
Unilateral effects were observed in left middle temporal gyrus and
right inferior temporal and right caudal ACC. Our ﬁndings of lower
cortical thickness in medial PFC and ACC are consistent with prior
meta-analyses.3–8 Our ﬁndings extend previous ﬁndings by
demonstrating structural abnormalities in the temporal lobe
(middle and inferior temporal and fusiform gyri), posterior
cingulate cortex and insula. The large sample also adds to ourT
ab
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Figure 2. Meta-analysed effect sizes for regions with a signiﬁcant
(PFDRo0.05) decrease in cortical surface area in adolescent major
depressive disorder (MDD) patients compared to healthy controls.
Negative effect sizes d indicate lower cortical surface area in MDD
compared to controls.
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Table 2. Full meta-analytic results for surface area of each structure for adolescent MDD patients vs controls comparison controlling for age, sex and
scan center
Cohen's d
(MDD vs CTL)
s.e. 95% CI % Difference P-value FDR
P-value
I2 No. of
controls
No. of
patients
Right lingual gyrus − 0.422 0.108 (−0.633 to − 0.211) − 5.870 9.12E-05 0.006 0.004 294 213
Right inferior parietal cortex − 0.384 0.108 (−0.595 to − 0.173) − 5.320 3.64E-04 0.013 0.001 293 213
Left precentral gyrus − 0.369 0.108 (−0.581 to − 0.157) − 4.071 6.51E-04 0.015 0.005 291 212
Left lingual gyrus − 0.367 0.116 (−0.595 to − 0.139) − 5.165 0.002 0.020 11.038 294 213
Right cuneus − 0.353 0.160 (−0.667 to − 0.038) − 5.049 0.028 0.103 49.494 292 212
Left pericalcarine cortex − 0.339 0.108 (−0.55 to − 0.128) − 5.862 0.002 0.020 0.012 294 213
Left cuneus − 0.336 0.182 (−0.693 to 0.021) − 5.031 0.065 0.162 60.682 294 213
Right pericalcarine cortex − 0.332 0.108 (−0.543 to − 0.12) − 5.548 0.002 0.020 0.005 293 212
Left lateral occipital cortex − 0.330 0.108 (−0.541 to − 0.119) − 4.253 0.002 0.020 0.002 294 212
Left medial orbitofrontal cortex − 0.329 0.109 (−0.542 to − 0.116) − 5.162 0.002 0.020 o0.001 283 210
Right hemisphere total surface area − 0.325 0.108 (−0.536 to − 0.114) − 3.386 0.003 0.020 o0.001 294 213
Left hemisphere total surface area − 0.320 0.107 (−0.531 to − 0.11) − 3.332 0.003 0.020 o0.001 294 213
Right postcentral gyrus − 0.305 0.108 (−0.517 to − 0.094) − 3.651 0.005 0.027 o0.001 289 212
Right superior frontal gyrus − 0.305 0.107 (−0.516 to − 0.095) − 3.916 0.005 0.027 o0.001 294 213
Right caudal middle frontal gyrus − 0.288 0.136 (−0.555 to − 0.02) − 5.188 0.035 0.116 32.049 294 211
Left precuneus − 0.278 0.107 (−0.488 to − 0.068) − 3.540 0.010 0.052 o0.001 294 213
Right banks superior temporal sulcus − 0.266 0.108 (−0.477 to − 0.055) − 4.176 0.014 0.068 0.001 293 203
Right medial orbitofrontal cortex − 0.250 0.111 (−0.468 to − 0.032) − 3.850 0.025 0.096 3.586 282 211
Left postcentral gyrus − 0.248 0.108 (−0.459 to − 0.037) − 2.887 0.021 0.094 o0.001 293 212
Left rostral middle frontal gyrus − 0.247 0.109 (−0.461 to − 0.033) − 3.483 0.024 0.096 2.612 294 213
Left caudal middle frontal gyrus − 0.247 0.107 (−0.457 to − 0.037) − 4.068 0.021 0.094 o0.001 294 213
Left superior parietal cortex − 0.245 0.167 (−0.573 to 0.083) − 2.954 0.143 0.263 53.595 294 213
Right middle temporal gyrus − 0.227 0.107 (−0.438 to − 0.017) − 3.235 0.034 0.116 o0.001 293 206
Left superior frontal gyrus − 0.222 0.107 (−0.433 to − 0.012) − 2.722 0.038 0.122 o0.001 293 212
Right superior parietal cortex − 0.221 0.149 (−0.512 to 0.07) − 2.578 0.137 0.260 41.842 293 213
Right rostral middle frontal gyrus − 0.218 0.153 (−0.519 to 0.083) − 3.091 0.155 0.265 45.512 292 213
Right precentral gyrus − 0.213 0.107 (−0.424 to − 0.003) − 2.426 0.047 0.142 o0.001 290 213
Left banks superior temporal sulcus − 0.212 0.111 (−0.43 to 0.005) − 3.670 0.056 0.162 0.001 279 190
Left inferior parietal cortex − 0.205 0.111 (−0.422 to 0.013) − 2.937 0.065 0.162 4.975 294 213
Right pars orbitalis − 0.201 0.107 (−0.412 to 0.009) − 3.034 0.061 0.162 o0.001 294 211
Left paracentral gyrus − 0.200 0.107 (−0.41 to 0.011) − 2.797 0.063 0.162 o0.001 294 212
Left fusiform gyrus − 0.196 0.148 (−0.485 to 0.094) − 2.839 0.186 0.280 41.160 293 213
Left frontal pole − 0.194 0.123 (−0.435 to 0.048) − 3.013 0.116 0.243 19.476 294 213
Left caudal anterior cingulate cortex − 0.187 0.151 (−0.484 to 0.11) − 3.527 0.217 0.297 43.982 291 213
Right inferior temporal gyrus − 0.185 0.107 (−0.395 to 0.025) − 3.129 0.084 0.202 o0.001 291 213
Left rostral anterior cingulate cortex − 0.180 0.166 (−0.505 to 0.145) − 3.977 0.277 0.365 53.020 293 213
Right temporal pole − 0.180 0.107 (−0.39 to 0.03) − 2.926 0.093 0.217 o0.001 294 213
Left superior temporal gyrus − 0.179 0.109 (−0.393 to 0.035) − 2.237 0.101 0.221 o0.001 283 198
Right superior temporal gyrus − 0.179 0.108 (−0.39 to 0.032) − 2.104 0.097 0.219 0.588 292 208
Right precuneus − 0.178 0.134 (−0.44 to 0.085) − 2.306 0.184 0.280 30.353 294 213
Right posterior cingulate cortex − 0.175 0.114 (−0.399 to 0.049) − 2.696 0.125 0.243 8.684 293 213
Left pars triangularis − 0.166 0.107 (−0.376 to 0.044) − 2.557 0.122 0.243 0.005 293 213
Right parahippocampal gyrus − 0.165 0.107 (−0.376 to 0.045) − 2.706 0.123 0.243 o0.001 294 212
Right caudal anterior cingulate cortex − 0.155 0.107 (−0.365 to 0.056) − 2.998 0.149 0.263 o0.001 293 213
Right lateral occipital cortex − 0.154 0.107 (−0.364 to 0.056) − 2.035 0.150 0.263 o0.001 294 213
Left middle temporal gyrus − 0.152 0.110 (−0.367 to 0.064) − 2.255 0.168 0.279 o0.001 283 196
Right fusiform gyrus − 0.145 0.107 (−0.355 to 0.066) − 2.157 0.178 0.280 o0.001 294 211
Left supramarginal gyrus − 0.141 0.107 (−0.351 to 0.069) − 2.061 0.187 0.280 o0.001 292 213
Right insula − 0.141 0.107 (−0.352 to 0.069) − 1.930 0.188 0.280 o0.001 292 213
Right paracentral gyrus − 0.140 0.107 (−0.351 to 0.071) − 1.967 0.192 0.280 o0.001 291 213
Left entorhinal cortex − 0.137 0.108 (−0.348 to 0.074) − 3.056 0.202 0.289 o0.001 292 209
Right pars triangularis − 0.135 0.107 (−0.345 to 0.075) − 2.189 0.207 0.290 o0.001 293 213
Left temporal pole − 0.131 0.107 (−0.34 to 0.079) − 2.086 0.222 0.298 o0.001 294 213
Left inferior temporal gyrus − 0.110 0.108 (−0.322 to 0.101) − 1.824 0.305 0.396 o0.001 290 212
Right rostral anterior cingulate cortex − 0.110 0.136 (−0.376 to 0.156) − 2.501 0.418 0.504 31.569 292 212
Right isthmus cingulate cortex − 0.110 0.118 (−0.341 to 0.121) − 1.774 0.350 0.437 13.248 293 213
Left transverse temporal gyrus − 0.100 0.107 (−0.311 to 0.11) − 1.660 0.349 0.437 0.002 294 213
Left parahippocampal gyrus − 0.099 0.113 (−0.321 to 0.123) − 2.112 0.383 0.470 7.948 294 211
Left posterior cingulate cortex − 0.085 0.172 (−0.422 to 0.253) − 1.246 0.624 0.704 56.442 293 213
Left pars opercularis − 0.075 0.107 (−0.286 to 0.135) − 1.208 0.485 0.575 o0.001 293 211
Right lateral orbitofrontal cortex − 0.065 0.124 (−0.309 to 0.178) − 0.917 0.600 0.689 20.640 294 211
Right transverse temporal gyrus − 0.060 0.107 (−0.27 to 0.149) − 1.000 0.572 0.668 o0.001 294 213
Left pars orbitalis − 0.051 0.139 (−0.324 to 0.221) − 0.774 0.712 0.791 34.678 292 213
Left insula − 0.036 0.154 (−0.337 to 0.265) − 0.405 0.815 0.852 45.762 291 213
Right pars opercularis − 0.031 0.107 (−0.241 to 0.179) − 0.495 0.773 0.845 o0.001 292 213
Right supramarginal gyrus − 0.029 0.108 (−0.24 to 0.182) − 0.413 0.789 0.849 o0.001 288 211
Right entorhinal cortex − 0.021 0.109 (−0.235 to 0.193) −0.462 0.847 0.872 0.001 291 209
Left lateral orbitofrontal cortex 0.010 0.180 (−0.342 to 0.363) 0.152 0.955 0.955 60.017 294 213
Left isthmus cingulate cortex 0.016 0.121 (−0.221 to 0.253) 0.266 0.896 0.909 16.747 293 212
Right frontal pole 0.064 0.258 (−0.441 to 0.569) 0.989 0.803 0.851 80.174 294 213
Abbreviations: CI, conﬁdence interval; CTL, controls; FDR, false-discovery rate; MDD, major depressive disorder. Adjusted Cohen's d is reported.
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understanding of how reproducible and consistent these effects
are likely to be when surveying cohorts worldwide.
A key feature of these regions is their close interaction with the
limbic system, consistent with the general pathophysiological
model of MDD that posits dysfunctional limbic–cortical
circuits.27,28 The dorsal and rostral ACC are functionally hetero-
geneous, supporting task monitoring, conﬂict detection, emotion
regulation, social cognition and executive functions.29 The insular
cortex is similarly multifunctional and engaged in visceroception,
autonomic response regulation and attentional switches (for
example, Menon and Uddin30). These regions show consistent
structural differences in this cross-sectional morphometric study
that may contribute to the broad spectrum of emotional, cognitive
and behavioural disturbances observed in MDD.
Although effect sizes were relatively small (d − 0.08 to − 0.13,
percentage of difference − 0.5% to − 1.3%, with overall low-to-
medium heterogeneity among studies; that is, I2 for most regions
between 0% and 50%) and in the range of previously reported
hippocampal volume reduction,2 the medial OFC showed the
largest effect sizes (d − 0.13, percentage of difference − 1.1%).
The lower medial wall of the PFC (medial OFC according to the
Desikan–Killiany atlas21 in FreeSurfer) contains the subgenual ACC
(sgACC), subcallosal gyrus and medial OFC and has dense
connections to the hypothalamus as the primary site of stress
response regulation.31 These ﬁndings concur with postmortem
ﬁndings of OFC structural deﬁcits,32 OFC/sgACC-speciﬁc volu-
metric meta-analyses,8,33 correlations between OFC thickness and
cortisol levels34 and evidence of functional derangement of the
sgACC in depression.35 Recently, right medial OFC thickness
measured at baseline in healthy adolescent girls proved a strong
predictor of the onset of depression in a multivariate model.36 The
ventromedial PFC and OFC (including the sgACC) are critically
involved in reinforcement learning,37 fear responsiveness and the
adaptive control of emotions,38 which are disturbed in MDD, and
have been associated with both a non-response to therapy39,40
and a more unfavourable course of the illness.41 Distinct from our
hippocampal volume ﬁnding,2 these effects were detectable
already in ﬁrst-episode patients with a medial OFC/ACC and
insular focus, indifferent from recurrent patients who showed less
widespread changes compared to controls. Further, no correla-
tions with the number of episodes and no age-by-diagnosis
effects were detected. Although these observations are based on
cross-sectional data, we add to limited and conﬂicting reports of
longitudinal volumetric changes in MDD42,43 which suggest that
progressive cortical abnormalities with growing disease load does
not appear to be a general feature of depression.
With regard to age at onset, no signiﬁcant differences were
found between adult patients with an adolescent-onset (⩽21
years) and controls. In contrast, adult-onset was associated with
signiﬁcant cortical thinning in numerous frontal, cingulate and
temporal regions. Interestingly, our prior work2 showed hippo-
campal volume alterations in adolescent-onset but not adult-
onset patients. This result may suggest differential effects of
stress-related remodelling or interactions with brain maturational
mechanisms at different periods of disease onset. Cortical
structural deﬁcits were not found in adolescent-onset adult
patients. This, however, may in part be due to lower statistical
power in the smaller adolescent-onset compared with the adult-
onset patient samples (N= 472 vs N= 1214). In addition, the lack of
effects could perhaps be explained by the fact that adolescent-
onset patients were younger than the adult-onset groups. Hence,
greater cortical thinning in MDD may be more pronounced in
adult-onset patients if the disease effects interact with increased
aging of the brain,40,44 but see also Truong et al.9 Following this
logic, we performed a post-hoc moderator analysis examining the
effects of mean age of patients in each sample on cortical
thickness differences between adolescent-onset (adult) patients
and controls. Samples with a higher mean age of patients indeed
showed greater cortical thinning in the adolescent-onset group
compared with controls (Supplementary Figure S22). Though not
robust to conservative correction for multiple comparisons (trend-
level PFDR = 0.09 for the left medial OFC), this pattern ﬁts the lack
of detected thickness differences in our adolescent MDD vs
adolescent controls analysis. Prior studies have reported mixed
results with regard to cortical abnormalities in adolescent MDD,
showing increased,15,17 decreased14–16 or no differences in cortical
thickness.45 Cortical thickness decreases linearly during
adolescence46–49 owing to synaptic pruning, myelination and
other remodelling effects.50 In adolescent MDD, anxious and
depressed symptoms have been associated with greater cortical
thickness.19 In contrast, our current results and prior reports3–8
provide consistent evidence for cortical thinning in adult MDD.
These opposite effects would suggest a delay in maturation (that
is, delay in thinning) of cortical thickness in adolescent MDD,
resulting in greater cortical thickness during various stages of
brain maturation but thinner cortex eventually. A possible
explanation for the lack of cortical thickness effects in the current
study is that 70% of our adolescents were 18–21 years, perhaps
older than the most sensitive period to detect maturation
delays.17,19 Of note, although not signiﬁcant, the left lateral OFC
showed a medium effect size (d − 0.31, percentage of difference
− 1.9%) for cortical thinning in adolescent MDD compared to
controls, whereas cortical alterations in other regions were
less clear.
Cortical surface area
Adult MDD patients showed no surface area abnormalities
compared to controls. However, adolescent patients revealed
smaller left and right hemisphere total surface areas, reﬂecting a
diffuse pattern of local surface area deﬁcits (effect sizes d between
− 0.31 to − 0.42, percentage of difference − 3.3 to − 5.9%). Similar
to cortical thickness alterations in adult MDD we observed surface
area deﬁcits in medial OFC and superior frontal gyrus, but also in
primary and higher order visual, somatosensory and motor areas.
These deﬁcits were observed in recurrent patients, suggesting a
negative effect of multiple episodes.
Cortical thinning starts from 2 to 4 years of age and continues
across the lifespan, but overall cortical surface area follows a
nonlinear and nonmonotonic developmental trajectory. The
cortical surface expands until about 12 years, remains relatively
stable and then decreases with age.46–49 Development of cortical
thickness and surface area are genetically independent12 and
result from different neurobiological processes,50 representing
distinct features of cortical development and aging. Cortical
surface area abnormalities were not detected in our early-onset
adult MDD patients, despite greater statistical power than for the
adolescent analyses, so smaller cortical surface area in adolescent
MDD may indicate delayed cortical maturation (that is, delayed
expansion). Some regions with surface area abnormalities,
including medial occipital regions (lingual gyrus), inferior parietal
cortex, precentral gyrus, medial OFC and superior frontal gyrus,
mature over a more prolonged time course during
adolescence47,49 and may be especially prone to a delay in
maturation in adolescent MDD. Such delayed maturation may
alter functional connections with other regions through decreases
in growth and branching of dendritic trees and the number of
synapses associated with gray matter volume,51 which may persist
into adult MDD even if surface area measures normalize when
transitioning into adulthood. The absence of cortical surface area
abnormalities in the adult MDD patients with an early age of onset
of depression could indicate such normalization; importantly,
however, we still detected weak negative associations between
severity of depressive symptoms and bilateral precuneus, left
frontal pole and left postcentral gyrus surface area.
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To our knowledge, alterations in cortical surface area abnorm-
alities have not been evaluated in adolescents with MDD. Surface
area deﬁcits of the ventromedial PFC and precuneus in children
and adolescents have been associated with higher anxiety,52 of
the lingual and temporal gyri in children with childhood
maltreatment,53 of prefrontal regions in children experiencing
early life adversity54 and of the OFC in adolescents with conduct
disorder.55 Importantly, early life stress, symptoms of anxiety and
externalizing problems in childhood and early adolescence are all
risk factors for early-onset MDD.56,57
Cortical thickness and surface area abnormalities were mainly
observed in ﬁrst-episode MDD and adolescent MDD, respectively;
this may indicate that cortical alterations are a feature of more
heterogeneous MDD samples, including adolescent and ﬁrst-
episode adult MDD individuals who may go on to other outcomes,
including bipolar or psychotic disorders, instead of adult MDD
samples with a more 'pure' depressive phenotype (in our study
characterized by recurrent MDD and adult MDD with an
adolescent-onset of depression in whom the illness is conﬁrmed
over time). Indeed, lower surface areas in many of the same
regions we observed in adolescent MDD in the current study were
prospectively predictive of poor functional outcomes in young
people with a clinically deﬁned risk of developing psychosis.58
Similar analyses currently underway in the ENIGMA Schizophrenia
and ENIGMA Bipolar Disorder working groups may clarify whether
regional cortical surface area and thickness are altered to a greater
extent in individuals with schizophrenia and bipolar disorder than
the alterations we observed in (adult) MDD. Nonetheless,
prospective studies are needed to conﬁrm this heterogeneity
hypothesis.
Limitations
We did not adjust the regional comparisons for average thickness
or total surface, respectively, as our main question was directed
towards regional MDD-related changes instead of identifying
regional effects that exceed a global effect. In contrast to surface
area measures, which are highly associated with global measures
of the brain (for example, intracranial volume, as a proxy for
overall brain size), cortical thickness does not scale proportio-
nately with brain size.59 In the current study, global deﬁcits in
cortical surface area (indicated by smaller left and right total
surface area) were observed in adolescents with MDD. Therefore,
our surface area results need to be interpreted as a diffuse, global
surface deﬁcit in adolescent MDD, with potential additional
regional accentuation.
Furthermore, we used a ⩽ 21-year cutoff for adolescent vs adult
MDD (cf. 'Introduction' section) consistent with our previous
work.2 Deﬁnitions of adolescent MDD in the literature are not
consistent, so alternative deﬁnitions might yield different results.
Ideally, age and age of onset effects on brain abnormalities in
MDD should be examined using a dimensional approach.
However, in the current meta-analysis the statistical analyses
were performed within each site, precluding this approach as few
samples covered the entire lifespan. In addition, the age
distribution of the adolescents (9% between 12 and 16 years,
21% between 16 and 18 years, 70% ⩾ 18 years) and the limited
adolescent sample size (while larger than prior reports) may not
be ideally sensitive to detect age-by-diagnosis interaction and
cortical thickness effects. Future addition of more adolescent MDD
samples to reﬂect a balanced age distribution may aid in detecting
cortical changes associated with MDD at different stages of brain
development.
In addition, when combining already collected data across
worldwide samples, data collection protocols are not prospec-
tively harmonized. Imaging acquisition protocols and clinical
assessments therefore differed across studies, which limits analysis
of sources of heterogeneity. The current study did not allow a
reliable investigation of antidepressant medication effects on
cortical structure because of its cross-sectional design and lack of
detailed information on history, duration and type and dosage of
antidepressant treatment. Still, in Supplementary Information SI1
we report on comparisons between patients taking antidepres-
sant, antidepressant-free patients and controls. Adult patients
using antidepressants showed robust and widespread effects of
cortical thinning, whereas non-users showed cortical thinning only
in the left medial OFC. However, this cross-sectional ﬁnding
should not be interpreted as contradicting generally observed
neuroprotective effects of antidepressants.60 It is likely con-
founded by clinical standards recommending antidepressant use
mainly for severe or chronic MDD. In adolescent MDD patients,
surface area deﬁcits were observed in antidepressant-free patients
and not in adolescents taking antidepressants. Clearly, interven-
tion studies with preantidepressant and postantidepressant
treatment comparisons of antidepressants are required to draw
valid conclusions on the impact of antidepressant use on cortical
structure.
CONCLUSIONS
Cortical structure is abnormal in numerous brain regions in adult
and adolescent MDD. Medial OFC was consistently implicated
across analyses—in adults, adolescents and analyses of clinical
correlations. This ﬁnding reinforces the hypothesized prominent
role of this region in depression throughout life. Other than
subcortical volumetric effects, cortical thickness changes were
robustly detectable in adult patients at their ﬁrst episode. MDD
may dynamically impact cortical development, and vice versa,
with different patterns of alterations at different stages of life.
Cortical thickness measurements showed greater differences than
surface area measures in adult MDD, but consistent surface area
deﬁcits were found in adolescent MDD. Cortical thickness and
surface area represent distinct morphometric features of the
cortex and may be differentially affected by depression at various
stages of life. Future (longitudinal) studies are needed to examine
dynamic changes in the cortical regions we examined here and to
relate such changes to symptom proﬁles, outcomes and treatment
responses in MDD.
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